HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma

Bookmark and Share
Published: 12 Jun 2020
Views: 104
Rating:
Save
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

Dr Elizabeth Plimack talks to ecancer in an online interview for the ASCO virtual meeting 2020 about the HCRN: GU16-260 study.

This was a phase II study of nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma.

Dr Plimack outlines the reasoning behind the study, and the results which showed a lack of response from the addition of ipilimumab.